WEEKLY MOUNJARO (tirzepatide) WEIGHT LOSS PROGRAM
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is composed of 39 amino acids and is an analog of the gastric inhibitory polypeptide. It enhances the insulin response, suppresses glucagon secretion, promotes satiety and improves insulin sensitivity. Tirzepatide works by helping the patient feel full on less food and slowing the passage of food through the digestive tract.
Vitamin B12 is a water-soluble vitamin that plays essential roles in red blood cell creation, cell metabolism, nerve function and production of DNA. It also works as a coenzyme in the conversion of protein and fat into energy.
Common side effects include:
- Nausea
- Vomiting
- Diarrhea
- Loss of appetite
- Stomach pain
- Constipation
- Upset stomach
Who should not take Tirzepatide?
Given the theoretical risk, Tirzepatide should be avoided in those with a personal or family history of medullary thyroid carcinoma. Patients with a history of MEN 2 (multiple endocrine neoplasia syndrome type-2) should also avoid Tirzepatide. Furthermore, patients who experience a hypersensitivity reaction should avoid using Tirzepatide any further. Other relative contraindications also exist, such as gallbladder disease or diabetic retinopathy.
Storage:
Tirzepatide should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C) and protected from light. It can be stored at room temperature for 21 days, if needed.
Pregnancy Use:
It’s not known whether it’s safe to use tirzepatide during pregnancy. The drug’s manufacturer recommends stopping tirzepatide at least 2 months before trying to become pregnant. This clinic will not prescribe tirzepatide to patients who are pregnant or breast feeding (no exceptions.)
